FDA Warning/“Untitled” Letters Will Be Reviewed By Chief Counsel

Division of Drug Marketing, Advertising & Communications "untitled" letters will be included in a new FDA policy requiring prior approval from the Office of the Chief Counsel before warning letters are issued